Laekna Therapeutics, a Shanghai, China-based clinical-stage biotechnology company, raised $61M in Series D funding.
The round was led by CS Capital with participation from Worldstar, Infinity Capital, Yanchuang Capital.
Led by CEO Dr. Chris Lu, Laekna is dedicated to developing next generation medicines to treat cancer and liver diseases. The company leverages a platform that has enabled the rapid development of 14 innovative drug candidates. The company has initiated six clinical programs, three of which are multi-regional clinical trials (including one pivotal trial) to address urgent, unmet medical needs in the standard of care-resistant cancers.
The company intends to use the funds to accelerate its development efforts. Proceeds from the Series D financing will be used to accelerate the clinical development of Laekna’s two core product candidates, AKT kinase inhibitor afuresertib (LAE002) and the world’s first clinical-stage CYP17/CYP11B2 dual inhibitor (LAE001). Both product candidates cover three differentiated key mechanisms, namely targeted therapy, hormonal therapy, and immuno-oncology therapy. Its most advanced clinical trial is an open-label, randomized, multi-regional Phase 2 PROFECTA-II clinical trial of afuresertib, the world’s first registration-directed clinical trial of an AKT kinase inhibitor to treat platinum-resistant ovarian cancer.